Severity
Moderate
FDA Drug recall · Reported May 1, 2024
Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.
Cipla USA, Inc. recalled Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-… - a moderate-severity action.
Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-… was recalled by Cipla USA, Inc. in May 1, 2024. Reason: Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact…. Check the official notice for the remedy. Verify recall #D-0471-2024 with the FDA Drug before acting.
The recall
Cipla USA, Inc. issued this moderate-severity FDA Drug recall-Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact….
Sourced from official FDA Drug enforcement records. Verify recall #D-0471-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0471-2024) was formally reported on May 1, 2024, with the manufacturer initiating the action on March 26, 2024. It is classified under Moderate severity (Class II), with a current status of Terminated. Cipla USA, Inc. is listed as the recalling firm, operating out of Warren, NJ. Federal records list the affected scope as 59244/3ml FFS packs.
The documented reason for this recall is: Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch. Distribution data in the federal record shows the product reached: USA nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
59244/3ml FFS packs
Related Recalls
6
5 from same agency
Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-dose vials, packaged in carton containing 30 vials ( 6 pouches of 5 - 3 mL vials), Rx only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-173-53
Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0471-2024 |
| Date reported | May 1, 2024 |
| Date initiated | March 26, 2024 |
| Recalling firm | Cipla USA, Inc. |
| Firm location | Warren, NJ |
| Affected scope | 59244/3ml FFS packs |
| Distribution | USA nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 1, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.